Anterolateral myocardial infarction
diseaseOn this page
Also known as acute anterior wall myocardial infarctionanterolateral myocardial infarctionsanteroseptal myocardial infarctionanteroseptal myocardial infarctionsinfarction, anterolateral myocardialinfarction, anteroseptal myocardialinfarctions, anterolateral myocardialinfarctions, anteroseptal myocardialmyocardial infarction, anterior wallmyocardial infarction, anterolateralmyocardial infarction, anteroseptalmyocardial infarctions, anterolateralmyocardial infarctions, anteroseptal
Summary
Anterolateral myocardial infarction (MONDO:0006652) is a disease and 5 clinical trials. Top therapeutic interventions include folic acid. A subtype of myocardial infarction — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 5
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | anterolateral myocardial infarction |
| Mondo ID | MONDO:0006652 |
| EFO | EFO:1000812 |
| MeSH | D056988 |
| DOID | DOID:5845 |
| ICD-11 | 687792216 |
| UMLS | C0262564 |
| MedGen | 78086 |
| MedDRA | 10068109 |
| Is cancer (heuristic) | no |
Also known as: acute anterior wall myocardial infarction · anterolateral myocardial infarction · anterolateral myocardial infarctions · anteroseptal myocardial infarction · anteroseptal myocardial infarctions · infarction, anterolateral myocardial · infarction, anteroseptal myocardial · infarctions, anterolateral myocardial · infarctions, anteroseptal myocardial · myocardial infarction, anterior wall · myocardial infarction, anterolateral · myocardial infarction, anteroseptal · myocardial infarctions, anterolateral · myocardial infarctions, anteroseptal
Disease family
This is a subtype of myocardial infarction. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › myocardial disorder › myocardial infarction › anterolateral myocardial infarction
Related subtypes (13): posteroinferior myocardial infarction, septal myocardial infarction, posterior myocardial infarction, apical myocardial infarction, subendocardial myocardial infarction, posterolateral myocardial infarction, inferolateral myocardial infarct, lateral myocardial infarction, silent myocardial infarction, anteroseptal myocardial infarction, acute myocardial infarction, myocardial stunning, inferior myocardial infarction
Subtypes (1): acute anterolateral myocardial infarction
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Plasmalyte A.
Clinical trials & evidence
Clinical trials
Clinical trials: 5.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03516903 | PHASE2/PHASE3 | TERMINATED | Effect of Methotrexate Carried by a Lipid Nanoemulsion on Left Ventricular Remodeling After STEMI |
| NCT05043610 | PHASE3 | COMPLETED | MSCs for Prevention of MI-induced HF |
| NCT00199823 | PHASE2 | COMPLETED | Autologous Stem Cell Transplantation in Acute Myocardial Infarction |
| NCT06463808 | Not specified | RECRUITING | Effect of Recombinant Human Brain Natriuretic Peptide on Ventricular Remodeling and Cardiac Function in Patients With Acute Anterior Myocardial Infraction Undergoing Percutaneous Coronary Intervention |
| NCT03233919 | Not specified | UNKNOWN | COmprehensive Remote Ischemic Conditioning in Myocardial Infarction |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FOLIC ACID | 4 | 1 |
Related Atlas pages
- Drugs: Folic Acid